… 10) is the fourth-generation EGFR inhibitor obtained by high-throughput screening (HTS)
strategy from a library of 2.5 million compounds at 1 µM ATP concentration. EAI001 57 is a …

… epithelial-derived tumors, and associated with poor prognosis and survival in cancer patients.
Here, we discuss in detail the role of EGFR in specific epithelial-derived … -EGFR therapies. …

… epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase
receptors… tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human …

… Epidermal growth factor receptor (EGFR) is of great … Currently, third-generation inhibitors
of EGFR, especially … d]pyrimidine derivative possessed more potent EGFR inhibition …

… EGFR inhibition in second-line therapy of mCRC patients after progression from first-line
treatment … Third-line treatment in patients with RAS WT mCRC who obtained a PR/CR in first …

… As the significant approach in the cancer targeted therapy, synthetic EGFR-TKIs have been
… conclusion, EGFR-TKIs are the standard first-line treatment to patients with advanced EGFR-…

… the use of EFGR-TKIs plus angiogenesis inhibitors as a first-line therapy for NSCLC. Mesh
and entry … prescribed drugs were checked to further derive qualified publications. Further, we …

… of single-agent EGFR inhibitors in the first-line setting. Similarly, adjuvant EGFR inhibitors, are
… Combining existing and new treatments with EGFR-targeted therapy is a potential strategy …

… applications in the detection and treatment of cancer. This … show limited wild-type EGFR
inhibition. Therefore these drugs do … derivatives and used in tumor imaging and treatment [173]. …

… the 9–14 months of treatment. (10−13) To overcome the resistance, a number of the
second-generation EGFR inhibitors targeting EGFR harboring T790M activating mutation have been …